title: Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
authors.affiliation: Department of Medical Oncology, University of Messina, Via Consolare Valeria, 98125 Messina, Italy. vpitini@unime.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Pitini
authors.forename: Antonio
authors.initials: A
authors.lastname: Cascio
authors.forename: Carmela
authors.initials: C
authors.lastname: Arrigo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Altavilla
mesh_terms: D000074323:Alemtuzumab; D000666:Amphotericin B / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000981:Antiprotozoal Agents; D000074323:Alemtuzumab; D000666:Amphotericin B